Dr Simon Teague

Biography

 Simon J. Teague PhD first studied chemistry at the University of Nottingham (1977-83). From 1983-85 he was a NATO scholar with A.I. Meyers at Colorado State University USA.  After this he worked at Astrazeneca in the UK as a senior medicinal chemist  (1985-2010). He then moved to Singapore to lead the chemistry programs aimed at the discovery of drugs for Dengue fever at the Novartis Institute for Tropical Diseases (2010-12). He first became a member of Kings College at the Wolfson Centre for Age Related Disease in 2012. In 2013 he established TeagueMedchem  LtD and initiated a collaboration with GSK at their open-source drug discovery laboratories in Madrid, carrying out projects aimed at the discovery of new anti-tuberculosis drugs.

Research Interest

 He specializes in the early stages of discovery using medicinal chemistry, high throughput screening and structure based design, employing techniques such as X-ray crystallography and robotics. He is best known for first expounding the concept of “lead-like” (rule of 3) following Lipinski´s famous publication on “drug-like” (rule of 5). The concept of lead-like has become part of the common language of medicinal chemistry and has been incorporated into quality measures used throughout the pharmaceutical industry, such as Lipophilic Ligand Efficiency (LLE).